Clinical Study to Evaluate the IBS Symptoms Improving Effect and Safety of GTB1
NCT ID: NCT05277428
Last Updated: 2022-05-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
27 participants
INTERVENTIONAL
2020-11-01
2022-01-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
To Study the Efficacy and Safety of L. Plantarum UALp-05TM in Diarrhea- Predominant-irritable Bowel Syndrome
NCT04950296
The Efficacy of Single-strain Probiotics in Patients With Irritable Bowel Syndrome
NCT05064930
Exploring the Mechanism of a Probiotic Combination VSL#3 in Irritable Bowel Syndrome
NCT00786123
The Effects of Multi-strain Probiotics in Adults With Diarrhea Predominant Irritable Bowel Syndrome
NCT01637714
Study to Determine Efficacy of Probiotics in Irritable Bowel Syndrome
NCT02545413
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lactobacillus Plantarum APsulloc 331261(GTB1)
Take GTB1 capsule once daily for 4 weeks
GTB1
2 capsule/day
Placebo
Take placebo capsule once daily for 4 weeks.
Placebo
2 capsule/day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GTB1
2 capsule/day
Placebo
2 capsule/day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed case of IBS using Rome IV criteria
* Who had type 6 or 7 stools according to the BSFS on at least 2 weeks ≥ 25%
* Who voluntarily agreed to participate in the study and signed an informed consent form
Exclusion Criteria
* Who had antibiotic agents during the 4 weeks prior to study entry
* Women who is pregnant /breast-feeding, or who has childbearing potential and does not use available contraceptives
* Who is determined ineligible for study participation by investigators for any other reasons
19 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amorepacific Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jonghwa Roh, PhD
Role: STUDY_DIRECTOR
Amorepacific R&I center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Amorepacific
Yongin-si, Gyeonggi-do, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AP-AR-2020-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.